{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470629762
| IUPAC_name = 3-[(23''S'',24''R'')-14-ethenyl-5-(3-methoxy-3-oxopropyl)-22,23-''bis''(methoxycarbonyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[16.6.1.1<sup>3,6</sup>.1<sup>8,11</sup>.1<sup>13,16</sup>.0<sup>19,24</sup>]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid
| image = Verteporfin.svg
<!--Clinical data-->
| tradename = Visudyne
| Drugs.com = {{drugs.com|monograph|verteporfin}}
| MedlinePlus = a607060
| pregnancy_US = C
| legal_US = Rx-only
| routes_of_administration = [[Intravenous therapy|Intravenous]]
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 129497-78-5
| ATC_prefix = S01
| ATC_suffix = LA01
| ATC_supplemental =  
| PubChem = 5362420
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00460
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 21106402
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0X9PA28K43
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01162
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 60775
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2218885
<!--Chemical data-->
| C=41 | H=42 | N=4 | O=8
| molecular_weight = 718.794 g/mol
| smiles = COC(=O)[C@@H]2C(=C\C=C3\c1cc6nc(cc5nc(cc4nc(cc(n1)[C@]23C)C(/C)=C4/CCC(=O)OC)c(CCC(O)=O)c5C)C(/C=C)=C6/C)/C(=O)OC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h9-10,13,16-19,38,43,45H,1,11-12,14-15H2,2-8H3,(H,46,47)/b31-16-,33-18-,34-17-,35-19-/t38-,41+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZCQHFRFEJXRZDF-YWANUUMDSA-N
}}

'''Verteporfin''' (trade name '''Visudyne'''), a [[benzoporphyrin]] derivative, is a [[medication]] used as a [[photosensitizer]] for [[photodynamic therapy]] to eliminate the abnormal [[blood vessel]]s in the [[human eye|eye]] associated with conditions such as the wet form of [[macular degeneration]]. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a [[wavelength]] of 689&nbsp;nm<ref>{{cite web|url=http://www.bausch.com/Portals/109/-/m/BL/United%20States/Files/Package%20Inserts/Pharma/visudyne-package-insert.pdf |title=Visudyne package insert}}</ref> in the presence of [[oxygen]], produces highly reactive short-lived singlet oxygen and other reactive [[oxygen radical]]s, resulting in local damage to the [[endothelium]] and blockage of the vessels.<ref name="Drugs.com">Verteporfin {{drugs.com|monograph|verteporfin}}</ref><ref name=Scott2000>{{Cite journal 
| doi = 10.2165/00002512-200016020-00005 
| last1 = Scott | first1 = L. J. | last2 = Goa | first2 = K. L. | title = Verteporfin 
| journal = Drugs & aging | volume = 16 | issue = 2 | pages = 139–146; discussion 146–8 | year = 2000 | pmid = 10755329
}}</ref>

Verteporfin is also used [[Off-label use|off-label]] for the treatment of [[central serous retinopathy]].<ref>{{Cite journal 
| last1 = Adelman | first1 = R. 
| last2 = Adelman | first2 = R. A. 
| doi = 10.2147/OPTH.S32177 
| title = Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy 
| journal = Clinical Ophthalmology 
| volume = 7 
| pages = 1867–1875 
| year = 2013 
| pmid = 24092965 
| pmc =3788817 
}}</ref>

==Administration==
Verteporfin is given [[intravenous therapy|intravenous]]ly, 15 minutes before laser treatment.<ref name="Drugs.com" />

==Contraindications==
[[Porphyria]].<ref name="Drugs.com" />

==Side effects==
Most common side effects are blurred vision, headache, and local effects at the injection site. Also, [[photosensitivity]]; it is advised to avoid exposure to sunlight and unscreened lighting until 48&nbsp;hours after the injection of verteporfin.<ref name="Drugs.com" />

==Interactions==

Verteporfin is known to interact with the herbal remedy [[Tanacetum parthenium|feverfew]] (''Tanacetum parthenium''), the latter of which seems to act as an antagonist to verteporfin for unknown reasons. Taking the two substances simultaneously is inadvisable.<ref>{{cite web |url=http://www.drugs.com/drug-interactions/feverfew-with-verteporfin-2368-0-2298-0.html |title=Feverfew and Verteporfin Interactions |accessdate=14 April 2015}}</ref> 

Verteporfin has no influence on the liver enzyme [[CYP3A4]], which metabolises many pharmaceutical drugs.<ref name="Drugs.com" />

==References==
{{reflist}}

==External links ==
*[http://www.visudyne.com/ Novartis website for Visudyne]
*[http://discovery.ucl.ac.uk/374951/ Research into using verteporfin to treat pancreatic cancer]

{{Ocular vascular disorder agents}}
{{Intracellular chemotherapeutic agents}}

[[Category:Photosensitizing agents]]
[[Category:Ophthalmology drugs]]